ArticleCureus2025
Drug-Induced Lung Injury With Drug Eruption Due to Apalutamide Followed by Switch to Bicalutamide: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor inhibitors (ARIs) are the first-line treatment for castration-resistant prostate cancer. However, there have been limited reports on drug-induced lung injury (DILD) and other serious adverse events. We report the case of an 85-year-old Japanese man who was diagnosed with prostate cancer and initiated treatment with apalutamide. Approximately two months later, he developed DILD accompanied by a drug eruption. After recovery, the patient was switched to bicalutamide, and the drug eruption recurred; however, DILD did not develop. We suspected cross-reactivity in the drug eruption but not in the interstitial lung injury. This case suggests that medical practitioners should be careful concerning the development of drug eruption and DILD when switching from one ARI to another when DILD develops in an ARI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.